Business Context and Reporting Period
The filing is Greatbatch, Inc.’s Form 10-K for the fiscal year ended January 2, 2015, not Integer Holdings Corp. The company operates through Greatbatch Medical and QiG, supplying medical-device components, assemblies, batteries, orthopaedic products, vascular products, and emerging neuromodulation systems. Fiscal 2014 contained 52 weeks; fiscal 2013 contained 53 weeks.
Greatbatch acquired Centro de Construcción de Cardioestimuladores del Uruguay (CCC) in August 2014 for $19.8 million, funded with cash. CCC contributed approximately $5.8 million of revenue and $1.2 million of net income in fiscal 2014.
Key Financial Metrics
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Sales | $687.8 million | $663.9 million | Up 4% |
| Gross profit | $231.4 million | $219.3 million | Up 6% |
| Gross margin | 33.6% | 33.0% | Up 60 basis points |
| Operating income | $75.7 million | $61.3 million | Up 23% |
| Operating margin | 11.0% | 9.2% | Up 180 basis points |
| Net income | $55.5 million | $36.3 million | Up 53% |
| Diluted EPS | $2.14 | $1.43 | Up 50% |
| Adjusted operating income | $91.2 million | $82.9 million | Up 10% |
| Adjusted operating margin | 13.3% | 12.5% | Up 80 basis points |
| Adjusted diluted EPS | $2.42 | $2.10 | Up 15% |
| Operating cash flow | $81.3 million | $56.8 million | Up $24.5 million |
| Capital expenditures | $24.8 million | $18.6 million | Up $6.2 million |
| Cash and equivalents | $76.8 million | $35.5 million | Up $41.4 million |
| Total debt | $187.5 million | $197.5 million | Down $10.0 million |
Fiscal fourth-quarter 2014 sales were $169.7 million, gross profit was $57.2 million, net income was $14.2 million, and diluted EPS was $0.54. Fourth-quarter 2013 included an additional fiscal week.
Working capital was $242.0 million and the current ratio was 3.23 at year-end. The company had $300 million of available revolving borrowing capacity. Its adjusted EBITDA-to-interest ratio was 34.7 to 1.0 versus a 3.0 to 1.0 minimum covenant, and its total leverage ratio was 1.29 to 1.0 versus a maximum of 4.5 to 1.0. Long-term debt matures principally through 2019, with $120.0 million of scheduled principal payments in 2019.
Material Changes Versus the Prior Comparable Period
- Greatbatch Medical sales increased 3% to $678.3 million. Orthopaedics increased 13%, vascular increased 22%, and energy, military and environmental increased 5%.
- Cardiac and neuromodulation sales declined 1%, reflecting customer inventory reductions, pricing pressure, customer diversification, and the end-of-life transition for two legacy products that generated approximately $22 million of 2014 sales.
- Portable Medical sales declined 12% as the company discontinued or reduced lower-margin programs and refocused on more profitable products.
- QiG sales increased 212% to $9.5 million, driven by CCC, thin-film electrode adoption, and new product launches. QiG remained loss-making, with a segment operating loss of $23.3 million.
- Gross margin improved through production efficiencies, higher volume, and productivity initiatives, partly offset by contractual price concessions and a less favorable product mix.
- Net research, development and engineering expense declined 8% to $49.8 million, primarily because Algovita design-verification testing was largely completed.
- Other operating expenses were $15.3 million, including $8.9 million related to capacity, capability, and resource-alignment initiatives. The company expects additional restructuring and facility-transfer spending.
- Interest expense declined 62% to $4.3 million, primarily because the company repaid $198 million of convertible subordinated notes in 2013 and reduced outstanding debt.
- A $4.4 million net gain on cost and equity-method investments benefited 2014 results, including a $3.2 million pretax gain from selling an investment.
Guidance, Outlook, Risks and Unusual Items
Management’s 2015 guidance calls for sales of $715 million to $730 million, GAAP diluted EPS of $2.02 to $2.12, adjusted diluted EPS of $2.61 to $2.71, GAAP operating margin of 10.7% to 11.0%, adjusted operating margin of 13.7% to 14.0%, capital expenditures of $35 million to $45 million, and approximately 25% and 26% GAAP and adjusted effective tax rates, respectively. Guidance excludes potential Algovita commercialization and additional acquisitions.
- Management expected first-quarter 2015 sales to decline in the high-single-digit percentage range because of customer inventory actions, legacy-product end-of-life effects, currency pressure, and a difficult prior-year comparison.
- Algovita, the company’s spinal cord stimulation system, received European CE Mark approval in June 2014, while FDA PMA approval was expected in the first half of 2015. Commercialization was not included in guidance.
- The company plans facility transfers to Mexico, a new portable-medical facility, an R&D hub, and a commercial operations hub. Expected capital investment for the 2014 capacity initiative was $25 million to $27 million, with more than $20 million of expected annual cost savings after completion.
- Principal risks include dependence on four customers representing 54% of sales, customer pricing and inventory actions, product obsolescence, regulatory approval and product-liability exposure, recalls and field actions, limited raw-material suppliers, foreign currency movements, healthcare regulation, acquisition integration, and execution of restructuring programs.
- A voluntary corrective action affected Standard Offset Cup Impactors manufactured and distributed from 2004 through 2013 because sterilization instructions did not meet sterility-assurance requirements. Three potentially related complaints were reported, with no adverse events reported.
- Intangible assets totaled $440.0 million, or 46% of total assets, including $354.4 million of goodwill. Future impairment charges remain a material sensitivity if operating conditions deteriorate.
- The company reported no material off-balance-sheet arrangements. Deloitte & Touche issued unqualified opinions on the financial statements and internal control over financial reporting; CCC was excluded from management’s 2014 internal-control assessment because it was acquired during the year.
Most Important Facts to Verify
- Confirm the issuer identity: the supplied filing is for Greatbatch, Inc., whereas the request identifies Integer Holdings Corp.
- Reconcile GAAP results with adjusted results, especially the $15.3 million of other operating expenses and the $4.4 million investment gain.
- Assess whether the projected decline in cardiac and neuromodulation sales and portable-medical sales is offset by orthopaedic, vascular, and new-product growth.
- Monitor Algovita’s FDA approval, commercialization economics, and the level of future QiG investment required.
- Evaluate customer concentration, contract minimum-purchase provisions, pricing concessions, and inventory-management practices.
- Review debt maturities, covenant calculations, interest-rate hedges, and the company’s planned $35 million to $45 million of 2015 capital spending.
- Track restructuring costs, facility transfers, expected savings, and potential operational disruption.
- Review the CCC purchase-price allocation, which remained preliminary at year-end, and the integration of CCC into internal controls.